Beta-blockers in Pulmonary Arterial Hypertension

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Pulmonary Arterial Hypertension

In brief

The investigators will conduct a, randomized, phase 2, placebo-controlled, double-blinded, crossover trial of carvedilol in 26 PAH patients with World Health Organization functional class II or III symptoms and RV ejection fraction (EF) \< 45% for 6 months.

Key facts

Study ID
NCT02507011
Run by
University of Minnesota
People needed
2
Starts
2016-01-31
Expected to finish
2019-07-01
Last updated by the study team
2020-06-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.